Trial Profile
CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacodynamics
- 01 Jun 2022 Primary endpoint has been met. (Change in the absolute number of CMV-induced adaptive NK cells (CD56dimCD57+NKG2C+) between days 28 and 100 post-auto-HCT in patients with lymphoid malignancies.), as per Results published in the Transplantation and Cellular Therapy
- 01 Jun 2022 Results published in the Transplantation and Cellular Therapy
- 31 Dec 2019 Status changed from active, no longer recruiting to completed.